|
1
|
Pasterkamp G, de Kleijn DP and Borst C:
Arterial remodeling in atherosclerosis, restenosis and after
alteration of blood flow: Potential mechanisms and clinical
implications. Cardiovasc Res. 45:843–852. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davis-Dusenbery BN, Wu C and Hata A:
Micromanaging vascular smooth muscle cell differentiation and
phenotypic modulation. Arterioscler Thromb Vasc Biol. 31:2370–2377.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Small EM and Olson EN: Pervasive roles of
microRNAs in cardiovascular biology. Nature. 469:336–342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fazi F and Nervi C: MicroRNA: Basic
mechanisms and transcriptional regulatory networks for cell fate
determination. Cardiovasc Res. 79:553–561. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan EK, Ceribelli A and Satoh M:
MicroRNA-146a in autoimmunity and innate immune responses. Ann
Rheum Dis. 72 Suppl 2:ii90–ii95. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo M, Mao X, Ji Q, Lang M, Li S, Peng Y,
Zhou W, Xiong B and Zeng Q: MiR-146a in PBMCs modulates Th1
function in patients with acute coronary syndrome. Immunol Cell
Biol. 88:555–564. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen
H, Dean DB and Zhang C: MicroRNA expression signature and
antisense-mediated depletion reveal an essential role of microRNA
in vascular neointimal lesion formation. Circ Res. 100:1579–1588.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li K, Ching D, Luk FS and Raffai RL:
Apolipoprotein E enhances microRNA-146a in monocytes and
macrophages to suppress nuclear factor-κB-driven inflammation and
atherosclerosis. Circ Res. 117:e1–e11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong S, Xiong W, Yuan J, Li J, Liu J and
Xu X: MiRNA-146a regulates the maturation and differentiation of
vascular smooth muscle cells by targeting NF-κB expression. Mol Med
Rep. 8:407–412. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Creemers EE, Tijsen AJ and Pinto YM:
Circulating microRNAs: Novel biomarkers and extracellular
communicators in cardiovascular disease? Circ Res. 110:483–495.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Rooij E and Olson EN: MicroRNA
therapeutics for cardiovascular disease: Opportunities and
obstacles. Nat Rev Drug Discov. 11:860–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li L, Chen XP and Li YJ: MicroRNA-146a and
human disease. Scand J Immunol. 71:227–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Taganov KD, Boldin MP, Chang KJ and
Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an
inhibitor targeted to signaling proteins of innate immune
responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006;
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bhaumik D, Scott GK, Schokrpur S, Patil
CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses
NF-kappaB activity with reduction of metastatic potential in breast
cancer cells. Oncogene. 27:5643–5647. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pauley KM, Satoh M, Chan AL, Bubb MR,
Reeves WH and Chan EK: Upregulated miR-146a expression in
peripheral blood mononuclear cells from rheumatoid arthritis
patients. Arthritis Res Ther. 10:R1012008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pacifico F, Crescenzi E, Mellone S,
Iannetti A, Porrino N, Liguoro D, Moscato F, Grieco M, Formisano S
and Leonardi A: Nuclear factor-{kappa}B contributes to anaplastic
thyroid carcinomas through up-regulation of miR-146a. J Clin
Endocrinol Metab. 95:1421–1430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang JF, Yu ML, Yu G, Bian JJ, Deng XM,
Wan XJ and Zhu KM: Serum miR-146a and miR-223 as potential new
biomarkers for sepsis. Biochem Biophys Res Commun. 394:184–188.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Curtiss LK and Boisvert WA: Apolipoprotein
E and atherosclerosis. Curr Opin Lipidol. 11:243–251. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu X, Dong Y, Chen S, Zhang G, Zhang M,
Gong Y and Li X: Circulating MicroRNA-146a and microRNA-21 predict
left ventricular remodeling after ST-elevation myocardial
infarction. Cardiology. 132:233–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wassmann S1, Wassmann K, Jung A, Velten M,
Knuefermann P, Petoumenos V, Becher U, Werner C, Mueller C and
Nickenig G: Induction of p53 by GKLF is essential for inhibition of
proliferation of vascular smooth muscle cells. J Mol Cell Cardiol.
43:301–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guevara NV, Kim HS, Antonova EI and Chan
L: The absence of p53 accelerates atherosclerosis by increasing
cell proliferation in vivo. Nat Med. 5:335–339. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghose J, Sinha M, Das E, Jana NR and
Bhattacharyya NP: Regulation of miR-146a by RelA/NFκB and p53 in
STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington's disease.
PLoS One. 6:e238372011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pestell RG: New roles of cyclin D1. Am J
Pathol. 183:3–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim MH, Ham O, Lee SY, Choi E, Lee CY,
Park JH, Lee J, Seo HH, Seung M, Choi E, et al: MicroRNA-365
inhibits the proliferation of vascular smooth muscle cells by
targeting cyclin D1. J Cell Biochem. 115:1752–1761. 2014.
View Article : Google Scholar : PubMed/NCBI
|
